Document Detail

Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
MedLine Citation:
PMID:  14690159     Owner:  NLM     Status:  MEDLINE    
The efficacy and safety of a single intravenous (I.V.) infusion of clodronate 1500 mg or 900 mg was compared with a single I.V. infusion of pamidronate 90 mg in the treatment of malignant hypercalcemia. Primary efficacy data from two separate, but parallel, randomized double-blind controlled multi-center studies (N = 63), involving patients with malignant hypercalcemia (S-Ca(cor) > 2.68 mmol/l), were pooled along with results from a study (N = 4), in which an open I.V. phase was followed by a randomized oral phase. The primary efficacy variable, the proportion of normocalcemic patients at day 5 could be evaluated from 51 subjects. Of them, 21 were in the clodronate 1500 mg group, 10 in the clodronate 900 mg group and 20 in the pamidronate 90 mg group. After the rehydration, the patients were given a single I.V. infusion of clodronate 1500 mg, clodronate 900 mg or pamidronate 90 mg. The patients were followed up for five days and S-Ca(cor) was measured daily. At day 5, a total of 16 patients (76%) in the clodronate 1500 mg group, six patients (60%) in the clodronate 900 mg group and 17 patients (85%) in the pamidronate 90 mg group were normocalcemic, the differences between the treatment groups being statistically non-significant. The differences in the mean S-Ca(cor) between the treatment groups were statistically non-significant. I.V. clodronate given either as 900 mg or 1500 mg single-dose was safe and well tolerated.
Sari T Atula; Riitta K Tähtelä; Jaakko I Nevalainen; Liisa H Pylkkänen
Related Documents :
15609019 - Volume expansion of albumin, gelatin, hydroxyethyl starch, saline and erythrocytes afte...
24281379 - Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacody...
23205809 - Dose-volume effects on brainstem dose tolerance in radiosurgery.
16698659 - Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly fo...
14635749 - Hydrocortisone dose and postoperative diabetes insipidus in patients undergoing transsp...
11345029 - Comparative evaluation of the efficiency of various ukrain doses in the combined treatm...
9886319 - Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with...
19401659 - Comparison of the effect of propofol and n-acetyl cysteine in preventing ischaemia-repe...
15092719 - Response of thermal stressed bobwhite to organophosphorus exposure.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Acta oncologica (Stockholm, Sweden)     Volume:  42     ISSN:  0284-186X     ISO Abbreviation:  Acta Oncol     Publication Date:  2003  
Date Detail:
Created Date:  2003-12-23     Completed Date:  2004-01-07     Revised Date:  2009-05-12    
Medline Journal Info:
Nlm Unique ID:  8709065     Medline TA:  Acta Oncol     Country:  Norway    
Other Details:
Languages:  eng     Pagination:  735-40     Citation Subset:  IM    
Schering Oy, Clinical Research, Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcium / blood
Clodronic Acid / therapeutic use*
Diphosphonates / therapeutic use
Double-Blind Method
Hypercalcemia / drug therapy*,  etiology
Infusions, Intravenous
Middle Aged
Neoplasms / complications*
Reg. No./Substance:
0/Diphosphonates; 10596-23-3/Clodronic Acid; 40391-99-9/pamidronate; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic counselling for cancer and risk perception.
Next Document:  Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for canc...